BioSpace News Archive

Aduhelm was approved by the U.S. FDA for its ability to clear beta-amyloid. Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.

The company aims to use the $100 million investment to support biotechnology firms involved in treating mental diseases and longevity projects.

Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

Researchers from Intermountain Healthcare played a key role in a new international study that has found that an antiviral drug designed to inhibit the ability of the SARS-CoV-2 virus to reproduce itself is effective at preventing severe illness from COVID when given early in the symptom course.

Aerogen Pharma, and Nuance Pharma (“Nuance”), today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.

Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older, and active psoriatic arthritis (PsA) in patients two years and older.

Leonhardt Ventures LLC, a pioneer in developing bioelectric and biologic innovations for organ regeneration and healing, today announced that the U.S. Patent and Trademark Office issued a pioneering U.S. patent for its novel multi-modality bioelectric stimulation system for treating cancer.

According to Yiling Pharmaceutical’s notice on Thursday (UTC+8) , the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued by China’s National Medical Products Administration (NMPA).

The global smart medical devices market is likely to witness growth at a CAGR of 7.8% during the forecast period of 2016 to 2024, according to the analysts of a new research report by Transparency Market Research.

According to the report, the global sepsis treatment market was valued over US$ 600 Mn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031.